Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:46 pm Sale |
2023-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
PERCEPTIVE ADVISORS LLC | 4,024,400 3.500% |
-1,254,562 (-23.77%) |
Filing History |
| 2024-02-14 4:05 pm Sale |
2023-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
Commodore Capital LP | 0 0.000% |
-5,738,500 (Position Closed) |
Filing History |
| 2024-02-14 12:50 pm Purchase |
2023-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
JANUS HENDERSON GROUP PLC JHG |
6,103,797 5.400% |
6,103,797 (New Position) |
Filing History |
| 2024-02-14 09:09 am Purchase |
2023-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
AVORO CAPITAL ADVISORS LLC | 16,337,739 9.990% |
3,537,739 (+27.64%) |
Filing History |
| 2024-02-13 5:02 pm Purchase |
2023-12-29 | 13G | CymaBay Therapeutics, Inc. CBAY |
The Vanguard Group | 6,306,149 5.560% |
2,879,138 (+84.01%) |
Filing History |
| 2024-02-13 4:27 pm Sale |
2023-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
TCG Crossover GP I, LLC | 0 0.000% |
-5,905,400 (Position Closed) |
Filing History |
| 2024-01-25 1:48 pm Purchase |
2023-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
BLACKROCK INC BLK |
9,610,239 8.500% |
7,662,206 (+393.33%) |
Filing History |
| 2023-09-22 4:30 pm Purchase |
2023-09-12 | 13G | CymaBay Therapeutics, Inc. CBAY |
RA Capital Management, L.P. | 6,940,000 6.200% |
6,940,000 (New Position) |
Filing History |
| 2023-09-11 4:45 pm Purchase |
2023-08-30 | 13G | CymaBay Therapeutics, Inc. CBAY |
ADAGE CAPITAL PARTNERS GP LLC | 3,685,625 3.760% |
1,525,475 (+70.62%) |
Filing History |
| 2023-03-10 2:04 pm Purchase |
2023-03-03 | 13G | CymaBay Therapeutics, Inc. CBAY |
PERCEPTIVE ADVISORS LLC | 5,278,962 5.600% |
5,278,962 (New Position) |
Filing History |
| 2023-02-14 4:06 pm Purchase |
2022-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
Commodore Capital LP | 5,738,500 6.800% |
318,604 (+5.88%) |
Filing History |
| 2023-02-14 2:23 pm Purchase |
2022-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
TCG Crossover GP I, LLC | 5,905,400 6.200% |
5,905,400 (New Position) |
Filing History |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | CymaBay Therapeutics, Inc. CBAY |
BLACKROCK INC BLK |
1,948,033 2.300% |
-3,376,095 (-63.41%) |
Filing History |
| 2022-02-14 4:22 pm Sale |
2021-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
Boxer Capital LLC | 0 0.000% |
-4,000,000 (Position Closed) |
Filing History |
| 2022-02-14 4:08 pm Purchase |
2021-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
Commodore Capital LP | 5,419,896 7.800% |
1,890,431 (+53.56%) |
Filing History |
| 2022-02-11 10:03 am Purchase |
2021-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
AVORO CAPITAL ADVISORS LLC | 12,800,000 14.700% |
2,500,000 (+24.27%) |
Filing History |
| 2022-02-01 5:08 pm Sale |
2021-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
BLACKROCK INC BLK |
5,324,128 6.300% |
-62,116 (-1.15%) |
Filing History |
| 2021-11-29 1:00 pm Purchase |
2021-11-22 | 13G | CymaBay Therapeutics, Inc. CBAY |
TCG Crossover Management LLC | 5,905,400 7.000% |
5,905,400 (New Position) |
Filing History |
| 2021-07-12 2:44 pm Purchase |
2021-06-30 | 13G | CymaBay Therapeutics, Inc. CBAY |
Commodore Capital LP | 3,529,465 5.100% |
3,529,465 (New Position) |
Filing History |
| 2021-02-16 4:04 pm Sale |
2020-12-31 | 13G | CymaBay Therapeutics, Inc. CBAY |
SHAW D E & CO L P | 1,260,749 1.800% |
-2,188,863 (-63.45%) |
Filing History |